These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28185789)

  • 1. Type I Interferons Modulate CD8
    De Beuckelaer A; Grooten J; De Koker S
    Trends Mol Med; 2017 Mar; 23(3):216-226. PubMed ID: 28185789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine Type I IFN Signaling in Dendritic Cells Stimulated with Fungal β-Glucans or Lipopolysaccharide Promotes CD8 T Cell Activation.
    Hassanzadeh-Kiabi N; Yáñez A; Dang I; Martins GA; Underhill DM; Goodridge HS
    J Immunol; 2017 Jan; 198(1):375-382. PubMed ID: 27872213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.
    De Beuckelaer A; Pollard C; Van Lint S; Roose K; Van Hoecke L; Naessens T; Udhayakumar VK; Smet M; Sanders N; Lienenklaus S; Saelens X; Weiss S; Vanham G; Grooten J; De Koker S
    Mol Ther; 2016 Nov; 24(11):2012-2020. PubMed ID: 27506450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I Interferons Regulate the Magnitude and Functionality of Mouse Polyomavirus-Specific CD8 T Cells in a Virus Strain-Dependent Manner.
    Qin Q; Shwetank ; Frost EL; Maru S; Lukacher AE
    J Virol; 2016 May; 90(10):5187-99. PubMed ID: 26984726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8+ T-cell priming regulated by cytokines of the innate immune system.
    Stäger S; Kaye PM
    Trends Mol Med; 2004 Aug; 10(8):366-71. PubMed ID: 15310456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I IFN signaling facilitates the development of IL-10-producing effector CD8
    Jiang L; Yao S; Huang S; Wright J; Braciale TJ; Sun J
    Eur J Immunol; 2016 Dec; 46(12):2778-2788. PubMed ID: 27701741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity.
    Liang Y; Hannan R; Fu YX
    Clin Cancer Res; 2021 Jul; 27(14):3818-3824. PubMed ID: 33692027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I interferons as vaccine adjuvants against infectious diseases and cancer.
    Bracci L; La Sorsa V; Belardelli F; Proietti E
    Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IRF-7 is the master regulator of type-I interferon-dependent immune responses.
    Honda K; Yanai H; Negishi H; Asagiri M; Sato M; Mizutani T; Shimada N; Ohba Y; Takaoka A; Yoshida N; Taniguchi T
    Nature; 2005 Apr; 434(7034):772-7. PubMed ID: 15800576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Lymphotoxin/Type I IFN Axis Programs CD8+ T Cells To Infiltrate a Self-Tissue and Propagate Immunopathology.
    Ng D; Maître B; Cummings D; Lin A; Ward LA; Rahbar R; Mossman KL; Ohashi PS; Gommerman JL
    J Immunol; 2015 Nov; 195(10):4650-9. PubMed ID: 26459352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling.
    Lindsay RW; Darrah PA; Quinn KM; Wille-Reece U; Mattei LM; Iwasaki A; Kasturi SP; Pulendran B; Gall JG; Spies AG; Seder RA
    J Immunol; 2010 Aug; 185(3):1513-21. PubMed ID: 20610651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory CD8(+) T cells elicited by HIV-1 lipopeptide vaccines display similar phenotypic profiles but differences in term of magnitude and multifunctionality compared with FLU- or EBV-specific memory T cells in humans.
    Figueiredo S; Charmeteau B; Surenaud M; Salmon D; Launay O; Guillet JG; Hosmalin A; Gahery H
    Vaccine; 2014 Jan; 32(4):492-501. PubMed ID: 24291199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety.
    Van der Jeught K; De Koker S; Bialkowski L; Heirman C; Tjok Joe P; Perche F; Maenhout S; Bevers S; Broos K; Deswarte K; Malard V; Hammad H; Baril P; Benvegnu T; Jaffrès PA; Kooijmans SAA; Schiffelers R; Lienenklaus S; Midoux P; Pichon C; Breckpot K; Thielemans K
    ACS Nano; 2018 Oct; 12(10):9815-9829. PubMed ID: 30256609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
    Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
    J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells.
    Wang C; Zhuang Y; Zhang Y; Luo Z; Gao N; Li P; Pan H; Cai L; Ma Y
    Vaccine; 2012 Jul; 30(32):4790-9. PubMed ID: 22634298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I and II interferons toward ideal vaccine and immunotherapy.
    Temizoz B; Ishii KJ
    Expert Rev Vaccines; 2021 May; 20(5):527-544. PubMed ID: 33993812
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.